lansoprazole has been researched along with Heartburn in 52 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Heartburn: Substernal pain or burning sensation, usually associated with regurgitation of gastric juice into the esophagus.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Complete sustained heartburn relief was achieved sooner with vonoprazan than with lansoprazole during the first week of therapy." | 9.30 | Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis. ( Arai, E; Fukui, H; Kondo, T; Miwa, H; Oshima, T; Taki, M; Tomita, T; Watari, J, 2019) |
| "To compare the clinical efficacy of the second-generation H2RA lafutidine with that of lansoprazole in Japanese patients with mild gastroesophageal reflux disease (GERD)." | 9.22 | Randomized study of lafutidine vs lansoprazole in patients with mild gastroesophageal reflux disease. ( Haruma, K; Inoue, M; Kawano, S; Kinoshita, Y; Komatsu, H; Komazawa, Y; Kushiyama, Y; Manabe, N; Mukai, S; Nagata, S; Okada, H; Okanobu, H; Onogawa, S; Takenaka, R; Tanaka, S; Todo, H; Yoshinaga, F, 2016) |
| "In this large-scale clinical study, lansoprazole effectively relieved dyspepsia in addition to reflux symptoms in patients with GERD." | 9.19 | Clinical characteristics and effectiveness of lansoprazole in Japanese patients with gastroesophageal reflux disease and dyspepsia. ( Haruma, K; Kinoshita, Y; Miwa, H; Miyata, K; Sanada, K, 2014) |
| "Dexlansoprazole appears to be effective in improving both heartburn and regurgitation, and this improvement is maintained for the duration of treatment." | 9.17 | Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease. ( Hunt, B; Mody, R; Perez, MC; Peura, DA; Pilmer, B, 2013) |
| "Most patients with GERD who take twice-daily PPI to control heartburn are able to successfully step down to once-daily dexlansoprazole 30 mg." | 9.16 | Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release. ( Fass, R; Han, C; Inadomi, J; Mody, R; O'Neil, J; Perez, MC, 2012) |
| "In patients with symptomatic GERD, dexlansoprazole MR 30 mg is significantly more efficacious than placebo in providing relief from nocturnal heartburn, in reducing GERD-related sleep disturbances and the consequent impairments in work productivity, and in improving sleep quality/quality of life." | 9.15 | The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD. ( Fass, R; Han, C; Johnson, DA; Mody, R; Orr, WC; Perez, MC; Pilmer, BL; Stern, KN, 2011) |
| "To assess efficacy and safety of dexlansoprazole MR in maintaining healed EO and heartburn relief." | 9.14 | Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis. ( Atkinson, SN; Howden, CW; Larsen, L; Metz, DC; O'Neil, J; Perez, MC, 2009) |
| "To evaluate the efficacy and safety of lansoprazole in self-treating subjects with frequent nocturnal heartburn." | 9.14 | Clinical trial: lansoprazole 15 or 30 mg once daily vs. placebo for treatment of frequent nighttime heartburn in self-treating subjects. ( Fennerty, MB; Peura, DA; Riff, DS; Snoddy, AM, 2009) |
| "To investigate the efficacy and safety of a 14-day treatment period with lansoprazole 15 mg for frequent heartburn in patients who are likely to select a nonprescription medication before consulting a prescriber." | 9.14 | Lansoprazole 15 mg once daily for 14 days is effective for treatment of frequent heartburn: results of 2 randomized, placebo-controlled, double-blind studies. ( Gilderman, L; Kushner, PR; Peura, DA; Snoddy, AM, 2009) |
| "Dexlansoprazole MR, a modified-release formulation of dexlansoprazole, an enantiomer of lansoprazole, effectively heals erosive oesophagitis." | 9.14 | Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis - maintenance of healing and symptom relief. ( Atkinson, SN; Howden, CW; Larsen, LM; Palmer, R; Perez, MC, 2009) |
| "Lansoprazole, at both the 15-mg and 30-mg doses, was very effective at a statistically significant level and was well tolerated in reducing frequent nighttime heartburn." | 9.14 | Patient self-treatment using lansoprazole for frequent nighttime heartburn. Commentary. ( Kushner, PR, 2010) |
| "To compare the efficacy and safety of on-demand lansoprazole 15 mg and placebo treatment in patients with gastro-oesophageal reflux." | 9.11 | Treatment of patients with heartburn without endoscopic evaluation: on-demand treatment after effective continuous administration of lansoprazole 15 mg. ( Bigard, MA; Genestin, E, 2005) |
| "05) lower percentages of days and nights with heartburn, less pain severity of both day and night heartburn, fewer days of antacid use, and smaller amounts of antacid use compared with patients who were treated with ranitidine or placebo." | 9.09 | Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. ( Campbell, DR; Fludas, C; Huang, B; Kahrilas, PJ; Richter, JE, 2000) |
| "Low-dose lansoprazole is more effective than low-dose omeprazole in the treatment of patients with mild heartburn or epigastric pain in general practice." | 9.09 | Low-dose lansoprazole provides greater relief of heartburn and epigastric pain than low-dose omeprazole in patients with acid-related dyspepsia. ( Crouch, SL; Jones, R, 1999) |
| "Daily diary data indicated that on the first treatment day a statistically significantly smaller percentage of lansoprazole patients reported daytime and night-time heartburn and antacid usage, compared with placebo patients." | 9.09 | Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis. ( Fisher, R; Greski-Rose, PA; Huang section sign, B; Kovacs, TO; Richter, JE, 1999) |
| "05) higher percentages of patients treated with lansoprazole than those treated with omeprazole did not experience a single episode of heartburn." | 9.09 | Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients. ( Huang, B; Kahrilas, PJ; Kovacs, TO; Pencyla, JL; Richter, JE; Sontag, SJ, 2001) |
| " In addition, because patients with higher BMI have more severe symptoms at baseline, they may experience greater therapeutic gain with dexlansoprazole (NERD and erosive oesophagitis) and possibly lansoprazole (erosive oesophagitis) treatment." | 7.79 | The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole. ( Hunt, B; Mody, R; Perez, MC; Peura, DA; Pilmer, B, 2013) |
| "We performed a retrospective analysis of data from 287 Helicobacter pylori-negative erosive esophagitis (EE) patients healed after 4 or 8 weeks of therapy with dexlansoprazole modified release (MR) or lansoprazole, and then randomized to placebo in 6-month maintenance trials." | 7.77 | Withdrawing PPI therapy after healing esophagitis does not worsen symptoms or cause persistent hypergastrinemia: analysis of dexlansoprazole MR clinical trial data. ( Han, C; Metz, DC; Perez, MC; Pilmer, BL, 2011) |
| "Heartburn was controlled on lansoprazole 30 mg/per day in 76." | 7.72 | Symptomatic and endoscopic outcome of heartburn 3-4.5 years after starting lansoprazole therapy: a prospective study of 142 patients. ( Abu Farsakh, N, 2003) |
| "Lansoprazole at individualized dosages was significantly more effective than laparoscopic fundoplication, in the short-term, in abolishing abnormal reflux in gastro-oesophageal reflux disease patients." | 7.71 | Laparoscopic fundoplication versus lansoprazole for gastro-oesophageal reflux disease. A pH-metric comparison. ( De Micheli, E; Frazzoni, M; Grisendi, A; Lanzani, A; Melotti, G, 2002) |
| "Complete sustained heartburn relief was achieved sooner with vonoprazan than with lansoprazole during the first week of therapy." | 5.30 | Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis. ( Arai, E; Fukui, H; Kondo, T; Miwa, H; Oshima, T; Taki, M; Tomita, T; Watari, J, 2019) |
| "To compare the clinical efficacy of the second-generation H2RA lafutidine with that of lansoprazole in Japanese patients with mild gastroesophageal reflux disease (GERD)." | 5.22 | Randomized study of lafutidine vs lansoprazole in patients with mild gastroesophageal reflux disease. ( Haruma, K; Inoue, M; Kawano, S; Kinoshita, Y; Komatsu, H; Komazawa, Y; Kushiyama, Y; Manabe, N; Mukai, S; Nagata, S; Okada, H; Okanobu, H; Onogawa, S; Takenaka, R; Tanaka, S; Todo, H; Yoshinaga, F, 2016) |
| "In this large-scale clinical study, lansoprazole effectively relieved dyspepsia in addition to reflux symptoms in patients with GERD." | 5.19 | Clinical characteristics and effectiveness of lansoprazole in Japanese patients with gastroesophageal reflux disease and dyspepsia. ( Haruma, K; Kinoshita, Y; Miwa, H; Miyata, K; Sanada, K, 2014) |
| "Dexlansoprazole appears to be effective in improving both heartburn and regurgitation, and this improvement is maintained for the duration of treatment." | 5.17 | Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease. ( Hunt, B; Mody, R; Perez, MC; Peura, DA; Pilmer, B, 2013) |
| "Most patients with GERD who take twice-daily PPI to control heartburn are able to successfully step down to once-daily dexlansoprazole 30 mg." | 5.16 | Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release. ( Fass, R; Han, C; Inadomi, J; Mody, R; O'Neil, J; Perez, MC, 2012) |
| "In patients with symptomatic GERD, dexlansoprazole MR 30 mg is significantly more efficacious than placebo in providing relief from nocturnal heartburn, in reducing GERD-related sleep disturbances and the consequent impairments in work productivity, and in improving sleep quality/quality of life." | 5.15 | The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD. ( Fass, R; Han, C; Johnson, DA; Mody, R; Orr, WC; Perez, MC; Pilmer, BL; Stern, KN, 2011) |
| "To assess efficacy and safety of dexlansoprazole MR in maintaining healed EO and heartburn relief." | 5.14 | Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis. ( Atkinson, SN; Howden, CW; Larsen, L; Metz, DC; O'Neil, J; Perez, MC, 2009) |
| "Esomeprazole may be more effective than omeprazole, lansoprazole, and pantoprazole for the rapid relief of heartburn symptoms and acid reflux symptoms in patients with reflux esophagitis." | 5.14 | Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis. ( Zheng, RN, 2009) |
| "To evaluate the efficacy and safety of lansoprazole in self-treating subjects with frequent nocturnal heartburn." | 5.14 | Clinical trial: lansoprazole 15 or 30 mg once daily vs. placebo for treatment of frequent nighttime heartburn in self-treating subjects. ( Fennerty, MB; Peura, DA; Riff, DS; Snoddy, AM, 2009) |
| "To investigate the efficacy and safety of a 14-day treatment period with lansoprazole 15 mg for frequent heartburn in patients who are likely to select a nonprescription medication before consulting a prescriber." | 5.14 | Lansoprazole 15 mg once daily for 14 days is effective for treatment of frequent heartburn: results of 2 randomized, placebo-controlled, double-blind studies. ( Gilderman, L; Kushner, PR; Peura, DA; Snoddy, AM, 2009) |
| "Dexlansoprazole MR, a modified-release formulation of dexlansoprazole, an enantiomer of lansoprazole, effectively heals erosive oesophagitis." | 5.14 | Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis - maintenance of healing and symptom relief. ( Atkinson, SN; Howden, CW; Larsen, LM; Palmer, R; Perez, MC, 2009) |
| "Lansoprazole, at both the 15-mg and 30-mg doses, was very effective at a statistically significant level and was well tolerated in reducing frequent nighttime heartburn." | 5.14 | Patient self-treatment using lansoprazole for frequent nighttime heartburn. Commentary. ( Kushner, PR, 2010) |
| "Single-dose esomeprazole was at least as effective as twice-daily lansoprazole for the primary end point of percentage of heartburn-free days during the study period (54." | 5.12 | Treatment of patients with persistent heartburn symptoms: a double-blind, randomized trial. ( Fass, R; Sontag, SJ; Sostek, M; Traxler, B, 2006) |
| "With 8 weeks' treatment, esomeprazole 40 mg once daily heals moderate to severe EE faster and in more patients, and resolves heartburn in more patients after 4 weeks of treatment, than lansoprazole 30 mg once daily." | 5.11 | Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis. ( Fennerty, MB; Hwang, C; Johanson, JF; Sostek, M, 2005) |
| "Heartburn, regurgitation and dysphagia were hardly found in any group at 8 weeks after 15 mg or 30 mg lansoprazole treatment." | 5.11 | Management of symptoms in step-down therapy of gastroesophageal reflux disease. ( Iida, T; Kishikawa, H; Mine, S; Tabata, T; Tanaka, Y, 2005) |
| "To compare the efficacy and safety of on-demand lansoprazole 15 mg and placebo treatment in patients with gastro-oesophageal reflux." | 5.11 | Treatment of patients with heartburn without endoscopic evaluation: on-demand treatment after effective continuous administration of lansoprazole 15 mg. ( Bigard, MA; Genestin, E, 2005) |
| "Rabeprazole may be more effective than omeprazole and lansoprazole for the rapid relief of heartburn symptoms in patients with reflux esophagitis." | 5.10 | Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole. ( Adachi, K; Fujishiro, H; Hamamoto, N; Hashimoto, T; Hattori, S; Hirakawa, K; Kaji, T; Katsube, T; Kinoshita, Y; Komazawa, Y; Mihara, T; Miyake, T; Niigaki, M; Ono, M; Shizuku, T; Suetsugu, H; Taniura, H; Yagi, J; Yamamoto, S, 2003) |
| "Esomeprazole (40 mg) is more effective than lansoprazole (30 mg) in healing erosive esophagitis and resolving heartburn." | 5.10 | Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. ( Castell, DO; Johnson, DA; Kahrilas, PJ; Levine, JG; Richter, JE; Skammer, W; Vakil, NB; Zuckerman, S, 2002) |
| "Low-dose lansoprazole is more effective than low-dose omeprazole in the treatment of patients with mild heartburn or epigastric pain in general practice." | 5.09 | Low-dose lansoprazole provides greater relief of heartburn and epigastric pain than low-dose omeprazole in patients with acid-related dyspepsia. ( Crouch, SL; Jones, R, 1999) |
| "Daily diary data indicated that on the first treatment day a statistically significantly smaller percentage of lansoprazole patients reported daytime and night-time heartburn and antacid usage, compared with placebo patients." | 5.09 | Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis. ( Fisher, R; Greski-Rose, PA; Huang section sign, B; Kovacs, TO; Richter, JE, 1999) |
| "05) lower percentages of days and nights with heartburn, less pain severity of both day and night heartburn, fewer days of antacid use, and smaller amounts of antacid use compared with patients who were treated with ranitidine or placebo." | 5.09 | Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. ( Campbell, DR; Fludas, C; Huang, B; Kahrilas, PJ; Richter, JE, 2000) |
| "Our objective was to compare four management strategies for heartburn: therapy with an H2-receptor antagonist (ranitidine), therapy with a proton pump inhibitor (lansoprazole), crossover from ranitidine to lansoprazole ("step-up" therapy), and crossover from lansoprazole to ranitidine ("step-down" therapy)." | 5.09 | Management of heartburn in a large, randomized, community-based study: comparison of four therapeutic strategies. ( Freston, JW; Henning, JM; Howden, CW; Huang, B; Lukasik, N, 2001) |
| "05) higher percentages of patients treated with lansoprazole than those treated with omeprazole did not experience a single episode of heartburn." | 5.09 | Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients. ( Huang, B; Kahrilas, PJ; Kovacs, TO; Pencyla, JL; Richter, JE; Sontag, SJ, 2001) |
| "In our study omeprazole was superior to either lansoprazole or pantoprazole in the maintenance treatment of complicated gastro-oesophageal reflux disease." | 5.08 | A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis. ( Diehl, KL; Geyer, P; Jaspersen, D; Martens, E; Schoeppner, H, 1998) |
| "The standard-dose esomeprazole 40 mg had more superiority in mucosal erosion healing and heartburn relief." | 4.95 | Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis. ( Li, MJ; Li, Q; Liu, LQ; Sun, M, 2017) |
| " In addition, because patients with higher BMI have more severe symptoms at baseline, they may experience greater therapeutic gain with dexlansoprazole (NERD and erosive oesophagitis) and possibly lansoprazole (erosive oesophagitis) treatment." | 3.79 | The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole. ( Hunt, B; Mody, R; Perez, MC; Peura, DA; Pilmer, B, 2013) |
| "We performed a retrospective analysis of data from 287 Helicobacter pylori-negative erosive esophagitis (EE) patients healed after 4 or 8 weeks of therapy with dexlansoprazole modified release (MR) or lansoprazole, and then randomized to placebo in 6-month maintenance trials." | 3.77 | Withdrawing PPI therapy after healing esophagitis does not worsen symptoms or cause persistent hypergastrinemia: analysis of dexlansoprazole MR clinical trial data. ( Han, C; Metz, DC; Perez, MC; Pilmer, BL, 2011) |
| "Heartburn was controlled on lansoprazole 30 mg/per day in 76." | 3.72 | Symptomatic and endoscopic outcome of heartburn 3-4.5 years after starting lansoprazole therapy: a prospective study of 142 patients. ( Abu Farsakh, N, 2003) |
| "Lansoprazole at individualized dosages was significantly more effective than laparoscopic fundoplication, in the short-term, in abolishing abnormal reflux in gastro-oesophageal reflux disease patients." | 3.71 | Laparoscopic fundoplication versus lansoprazole for gastro-oesophageal reflux disease. A pH-metric comparison. ( De Micheli, E; Frazzoni, M; Grisendi, A; Lanzani, A; Melotti, G, 2002) |
| "Rates of EE recurrence during the 24-wk maintenance period were 16." | 2.87 | Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole. ( Ashida, K; Hiramatsu, N; Hori, T; Iwakiri, K; Kudou, K; Nishimura, A; Sakurai, Y; Umegaki, E, 2018) |
| "pylori) eradication on gastroesophageal reflux disease is controversial." | 2.71 | The effect of Helicobacter pylori eradication on gastroesophageal reflux disease. ( Güliter, S; Kandilci, U, 2004) |
| "Management costs for gastroesophageal reflux disease are high because of the expensive medications used for maintenance therapy." | 2.71 | Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. ( Bernard, L; Fendrick, AM; Inadomi, JM; McIntyre, L, 2003) |
| "Lansoprazole was superior to ranitidine in providing relief of upper abdominal burning and daytime heartburn (p < 0." | 2.68 | Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy. ( Campbell, DR; Castell, D; Fleischmann, R; Kogut, DG; Lehman, GA; McFarland, M; Richter, J; Robinson, M; Sabesin, S; Sontag, SJ, 1997) |
| "Heartburn was a poor predictor of whether patients with chest pain were GORD-positive or GORD-negative by objective testing." | 2.47 | Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease. ( Howden, CW; Hughes, N; Kahrilas, PJ, 2011) |
| "Dexlansoprazole was well tolerated compared with placebo or lansoprazole in all studies." | 2.46 | Dexlansoprazole: A proton pump inhibitor with a dual delayed-release system. ( Emerson, CR; Marzella, N, 2010) |
| "The consequences of nocturnal gastroesophageal reflux disease (GERD) may be greater than daytime GERD in terms of clinical complications such as increased risk of esophageal lesions and respiratory conditions, as well as issues of health-related quality of life, sleep, work productivity, and economics." | 2.44 | Nocturnal gastroesophageal reflux disease: issues, implications, and management strategies. ( Johnson, DA; Katz, PO, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (9.62) | 18.2507 |
| 2000's | 31 (59.62) | 29.6817 |
| 2010's | 16 (30.77) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, MJ | 1 |
| Li, Q | 1 |
| Sun, M | 1 |
| Liu, LQ | 1 |
| Ashida, K | 1 |
| Iwakiri, K | 1 |
| Hiramatsu, N | 1 |
| Sakurai, Y | 1 |
| Hori, T | 1 |
| Kudou, K | 1 |
| Nishimura, A | 1 |
| Umegaki, E | 1 |
| Oshima, T | 1 |
| Arai, E | 1 |
| Taki, M | 1 |
| Kondo, T | 1 |
| Tomita, T | 1 |
| Fukui, H | 1 |
| Watari, J | 1 |
| Miwa, H | 2 |
| Peura, DA | 4 |
| Pilmer, B | 2 |
| Hunt, B | 2 |
| Mody, R | 4 |
| Perez, MC | 7 |
| Kinoshita, Y | 3 |
| Sanada, K | 1 |
| Miyata, K | 1 |
| Haruma, K | 2 |
| Giral, A | 1 |
| Kurt, R | 1 |
| Yeğin, EG | 1 |
| Yeğin, K | 1 |
| Takenaka, R | 1 |
| Okada, H | 1 |
| Kawano, S | 1 |
| Komazawa, Y | 2 |
| Yoshinaga, F | 1 |
| Nagata, S | 1 |
| Inoue, M | 1 |
| Komatsu, H | 1 |
| Onogawa, S | 1 |
| Kushiyama, Y | 1 |
| Mukai, S | 1 |
| Todo, H | 1 |
| Okanobu, H | 1 |
| Manabe, N | 1 |
| Tanaka, S | 1 |
| Johnson, DA | 3 |
| Katz, PO | 1 |
| Metz, DC | 2 |
| Howden, CW | 4 |
| Larsen, L | 1 |
| O'Neil, J | 2 |
| Atkinson, SN | 2 |
| Zheng, RN | 1 |
| Riff, DS | 1 |
| Snoddy, AM | 2 |
| Fennerty, MB | 2 |
| Kushner, PR | 2 |
| Gilderman, L | 1 |
| Larsen, LM | 1 |
| Palmer, R | 1 |
| Osipenko, MF | 1 |
| Bikbulatova, EA | 1 |
| Shakalite, IuD | 1 |
| Emerson, CR | 1 |
| Marzella, N | 1 |
| Juul-Hansen, P | 2 |
| Rydning, A | 3 |
| Fass, R | 4 |
| Orr, WC | 1 |
| Han, C | 3 |
| Stern, KN | 1 |
| Pilmer, BL | 2 |
| Kahrilas, PJ | 4 |
| Hughes, N | 1 |
| Hunt, R | 1 |
| Inadomi, J | 1 |
| Inadomi, JM | 1 |
| McIntyre, L | 1 |
| Bernard, L | 1 |
| Fendrick, AM | 1 |
| Abu Farsakh, N | 1 |
| Adachi, K | 1 |
| Hashimoto, T | 1 |
| Hamamoto, N | 1 |
| Hirakawa, K | 1 |
| Niigaki, M | 1 |
| Miyake, T | 1 |
| Taniura, H | 1 |
| Ono, M | 1 |
| Kaji, T | 1 |
| Suetsugu, H | 1 |
| Yagi, J | 1 |
| Mihara, T | 1 |
| Katsube, T | 1 |
| Fujishiro, H | 1 |
| Shizuku, T | 1 |
| Hattori, S | 1 |
| Yamamoto, S | 1 |
| Güliter, S | 1 |
| Kandilci, U | 1 |
| Rajabally, YA | 1 |
| Jacob, S | 1 |
| Johanson, JF | 1 |
| Hwang, C | 1 |
| Sostek, M | 2 |
| Ott, EA | 1 |
| Mazzoleni, LE | 1 |
| Edelweiss, MI | 1 |
| Sander, GB | 1 |
| Wortmann, AC | 1 |
| Theil, AL | 1 |
| Somm, G | 1 |
| Cartell, A | 1 |
| Rivero, LF | 1 |
| Uchôa, DM | 1 |
| Francesconi, CF | 1 |
| Prolla, JC | 1 |
| Mine, S | 1 |
| Iida, T | 1 |
| Tabata, T | 1 |
| Kishikawa, H | 1 |
| Tanaka, Y | 1 |
| Bigard, MA | 1 |
| Genestin, E | 1 |
| Sontag, SJ | 3 |
| Traxler, B | 1 |
| Dohmen, W | 1 |
| Fuchs, W | 1 |
| Umeda, N | 1 |
| Miki, K | 1 |
| Hoshino, E | 1 |
| Kogut, DG | 1 |
| Fleischmann, R | 1 |
| Campbell, DR | 2 |
| Richter, J | 1 |
| Robinson, M | 1 |
| McFarland, M | 1 |
| Sabesin, S | 1 |
| Lehman, GA | 1 |
| Castell, D | 1 |
| Jaspersen, D | 1 |
| Diehl, KL | 1 |
| Schoeppner, H | 1 |
| Geyer, P | 1 |
| Martens, E | 1 |
| Jones, R | 1 |
| Crouch, SL | 1 |
| Richter, JE | 4 |
| Kovacs, TO | 2 |
| Greski-Rose, PA | 1 |
| Huang section sign, B | 1 |
| Fisher, R | 1 |
| Huang, B | 3 |
| Fludas, C | 1 |
| Dupas, JL | 1 |
| Houcke, P | 1 |
| Samoyeau, R | 1 |
| McGuigan, JE | 1 |
| Henning, JM | 1 |
| Lukasik, N | 1 |
| Freston, JW | 1 |
| Raisch, DW | 1 |
| Klaurens, LM | 1 |
| Hayden, C | 1 |
| Malagon, I | 1 |
| Pulliam, G | 1 |
| Farup, PG | 1 |
| Juul-Hansen, PH | 1 |
| Cohen, JS | 1 |
| Melton, ST | 1 |
| Cimmino, A | 1 |
| Pencyla, JL | 1 |
| Castell, DO | 1 |
| Vakil, NB | 1 |
| Zuckerman, S | 1 |
| Skammer, W | 1 |
| Levine, JG | 1 |
| Hinder, RA | 1 |
| Frazzoni, M | 1 |
| Grisendi, A | 1 |
| Lanzani, A | 1 |
| Melotti, G | 1 |
| De Micheli, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparing Dexlansoprazole With Double-dose Lansoprazole to Achieve Sustained Symptomatic Response in Overweight and Obesity Patients With Reflux Esophagitis in Los Angeles Grades A & B[NCT02759393] | Phase 4 | 200 participants (Anticipated) | Interventional | 2015-10-31 | Enrolling by invitation | ||
| A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg Once-daily [QD] and 90 mg QD) and an Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis[NCT00251719] | Phase 3 | 2,054 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| A Phase 3 Study to Evaluate the Efficacy and Safety of Dexlansoprazole MR (30 mg QD and 60 mg QD) Compared to Placebo on Symptom Relief in Subjects With Symptomatic Nonerosive Gastroesophageal Reflux Disease (GERD)[NCT00321984] | Phase 3 | 947 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg Once- Daily [QD] and 90 mg QD) and an Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis[NCT00251693] | Phase 3 | 2,038 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| Effectiveness of Vonoprazan vs Omeprazole as Empiric Therapy for Gastroesophageal Reflux Disease (GERD) Patients Without Alarm Features in a Primary Care Setting: A Pragmatic, Randomized, Single Blind Study[NCT04028466] | Phase 4 | 82 participants (Actual) | Interventional | 2019-05-26 | Terminated (stopped due to Budget for the study was withdrawn and discontinued) | ||
| A Phase 3 Study to Evaluate the Safety and Efficacy of TAK-390MR (30 mg QD and 60 mg QD) Compared to Placebo in Maintenance of Healing in Subjects With Healed Erosive Esophagitis.[NCT00321737] | Phase 3 | 445 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| A Phase 3 Study to Evaluate the Safety and Efficacy of Dexlansoprazole MR (60 mg QD and 90 mg QD) Compared to Placebo in Maintenance of Healing in Subjects With Healed Erosive Esophagitis[NCT00255151] | Phase 3 | 451 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| A Phase 3 Study to Evaluate the Safety and Efficacy of Dexlansoprazole MR (60 mg QD and 90 mg QD) Compared to Placebo in Maintenance of Healing in Subjects With Healed Erosive Esophagitis[NCT00255164] | Phase 3 | 451 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| An Open-Label Trial of Dexlansoprazole 60mg for the Relief of Heartburn During the Fasting Month of Ramadan[NCT03079050] | Phase 4 | 33 participants (Actual) | Interventional | 2017-02-27 | Completed | ||
| A Phase 3 Multicenter, Randomized, Double-Blind, Parallel Group, Placebo Controlled Trial to Evaluate the Efficacy of TAK-390MR (30 mg QD) Compared to Placebo on Relief of Nocturnal Heartburn in Subjects With Symptomatic Gastroesophageal Reflux Disease (G[NCT00627016] | Phase 3 | 305 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| A Phase 3b Multicenter, Single-Blind Trial to Evaluate the Efficacy of Dexlansoprazole MR 30 mg in Maintaining Control of Gastroesophageal Reflux Disease Symptoms in Subjects on Prior Twice Daily Proton Pump Inhibitor Therapy[NCT00847808] | Phase 3 | 178 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| Economic Impact of Guidelines for Gastroesophageal Reflux Disease[NCT00057174] | 484 participants (Anticipated) | Interventional | Completed | ||||
| Dyspeptic Symptoms Evolution After Eradication of Helicobacter Pylori in Patients With Different Endoscopic Findings: a Randomized Double-blind Placebo-controlled Clinical Trial With 12 Months of Follow-up[NCT00404534] | Phase 3 | 407 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Percentage of subjects with baseline EE grade C or D combined who have complete healing of EE as assessed by endoscopy. Change in LA Classification grades C or D to healed was measured. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed. (NCT00251719)
Timeframe: Week 8
| Intervention | percentage of subjects (Number) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 77.8 |
| Dexlansoprazole MR 90 mg QD | 86.3 |
| Lansoprazole 30 mg QD | 78.9 |
Percentage of subjects with baseline EE grade C or D combined who have complete healing of EE as assessed by endoscopy. Change in LA Esophagitis Classification grades C or D to healed was measured. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed. (NCT00251719)
Timeframe: 8 Weeks
| Intervention | percentage of subjects (Number) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 87.6 |
| Dexlansoprazole MR 90 mg QD | 93.3 |
| Lansoprazole 30 mg QD | 87.7 |
Percentage of subjects with complete healing of EE as assessed by endoscopy. Change in LA Esophagitis Classification grades A, B, C, D to healed was measured. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed. (NCT00251719)
Timeframe: 4 Weeks
| Intervention | percentage of subjects (Number) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 69.7 |
| Dexlansoprazole MR 90 mg QD | 70.6 |
| Lansoprazole 30 mg QD | 65.4 |
Percentage of subjects with complete healing of EE as assessed by endoscopy. Change in LA Esophagitis Classification grades A, B, C, D to healed was measured. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed. (NCT00251719)
Timeframe: 4 Weeks
| Intervention | percentage of subjects (Number) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 80.1 |
| Dexlansoprazole MR 90 mg QD | 80.4 |
| Lansoprazole 30 mg QD | 77.0 |
Percentage of subjects with complete healing of EE as assessed by endoscopy. Change in LA Esophagitis Classification grades A, B, C, D to healed was measured. Healed is defined as anything that is less than the criterion for Grade A (greater than or equal to 1 mucosal break and less than 5 mm). If it doesn't meet the A criterion, it's counted as healed. (NCT00251719)
Timeframe: 8 Weeks
| Intervention | percentage of subjects (Number) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 86.9 |
| Dexlansoprazole MR 90 mg QD | 89.4 |
| Lansoprazole 30 mg QD | 84.6 |
Percentage of subjects with complete healing of EE as assessed by endoscopy. Change in LA Esophagitis Classification grades A, B, C, D to healed was measured. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed. (NCT00251719)
Timeframe: 8 Weeks
| Intervention | percentage of subjects (Number) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 93.1 |
| Dexlansoprazole MR 90 mg QD | 94.9 |
| Lansoprazole 30 mg QD | 91.5 |
The percentage was calculated as the days that were heartburn-free out of the total number of days for which either a daytime or nighttime result was marked. (NCT00321984)
Timeframe: 4 weeks
| Intervention | percentage of days (Mean) |
|---|---|
| Placebo QD | 25.0 |
| Dexlansoprazole MR 30 mg QD | 50.3 |
| Dexlansoprazole MR 60 mg QD | 49.1 |
The percentage was calculated as the days that were heartburn-free out of the total number of days for which either a daytime or nighttime result was marked. (NCT00321984)
Timeframe: 4 weeks
| Intervention | percentage of days (Median) |
|---|---|
| Placebo QD | 18.5 |
| Dexlansoprazole MR 30 mg QD | 54.9 |
| Dexlansoprazole MR 60 mg QD | 50.0 |
The percentage was calculated as the nights that were heartburn-free out of the total number of days for which a nighttime result was marked. (NCT00321984)
Timeframe: 4 weeks
| Intervention | percentage of days (Mean) |
|---|---|
| Placebo QD | 47.1 |
| Dexlansoprazole MR 30 mg QD | 67.6 |
| Dexlansoprazole MR 60 mg QD | 65.0 |
The percentage was calculated as the nights that were heartburn-free out of the total number of days for which a nighttime result was marked. (NCT00321984)
Timeframe: 4 weeks
| Intervention | percentage of days (Median) |
|---|---|
| Placebo QD | 51.7 |
| Dexlansoprazole MR 30 mg QD | 80.8 |
| Dexlansoprazole MR 60 mg QD | 76.9 |
Percentage of subjects with baseline EE grade C or D combined who have complete healing of erosive esophagitis as assessed by endoscopy for Change in LA Esophagitis Classification Grades C and D to healed. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed. (NCT00251693)
Timeframe: 8 Weeks
| Intervention | percentage of subjects (Number) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 79.7 |
| Dexlansoprazole MR 90 mg QD | 74.1 |
| Lansoprazole 30 mg QD | 65.0 |
Percentage of subjects with baseline EE grade C or D combined who have complete healing of EE as assessed by endoscopy for Change in LA Esophagitis Classification Grades C and D to healed. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed. (NCT00251693)
Timeframe: 8 Weeks
| Intervention | percentage of subjects (Number) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 88.9 |
| Dexlansoprazole MR 90 mg QD | 83.8 |
| Lansoprazole 30 mg QD | 74.5 |
Percentage of subjects with complete healing of EE as assessed by endoscopy was analyzed for change in LA Esophagitis Classification grades A, B, C, or D to healed. Healed is defined as anything that is less than the criterion for Grade A (greater than or equal to 1 mucosal break and less than 5 mm). If it doesn't meet the A criterion, it's counted as healed. (NCT00251693)
Timeframe: 8 Weeks
| Intervention | Percentage of subjects (Number) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 85.3 |
| Dexlansoprazole MR 90 mg QD | 85.8 |
| Lansoprazole 30 mg QD | 79.0 |
Percentage of subjects with complete healing of EE as assessed by endoscopy was analyzed for change in LA Esophagitis Classification grades A, B, C, or D to healed. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed. (NCT00251693)
Timeframe: 4 Weeks
| Intervention | Percentage of subjects (Number) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 66.2 |
| Dexlansoprazole MR 90 mg QD | 68.8 |
| Lansoprazole 30 mg QD | 64.8 |
Percentage of subjects with complete healing of EE as assessed by endoscopy was analyzed for change in LA Esophagitis Classification grades A, B, C, or D to healed. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed. (NCT00251693)
Timeframe: 4 Weeks
| Intervention | Percentage of subjects (Number) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 77.0 |
| Dexlansoprazole MR 90 mg QD | 78.8 |
| Lansoprazole 30 mg QD | 76.5 |
Percentage of subjects with complete healing of EE as assessed by endoscopy was analyzed for change in LA Esophagitis Classification grades A, B, C, or D to healed. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed. (NCT00251693)
Timeframe: 8 weeks
| Intervention | Percentage of subjects (Number) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 92.3 |
| Dexlansoprazole MR 90 mg QD | 92.2 |
| Lansoprazole 30 mg QD | 86.1 |
The percentage was calculated as the days that were heartburn-free out of the total number of days for which either a daytime or nighttime result was marked. (NCT00321737)
Timeframe: 6 months
| Intervention | Percentage of Days (Mean) |
|---|---|
| Placebo QD | 36.0 |
| Dexlansoprazole MR 30 mg QD | 83.3 |
| Dexlansoprazole MR 60 mg QD | 78.4 |
The percentage was calculated as the days that were heartburn-free out of the total number of days for which either a daytime or nighttime result was reported. (NCT00321737)
Timeframe: 6 months
| Intervention | Percentage of Days (Median) |
|---|---|
| Placebo QD | 28.6 |
| Dexlansoprazole MR 30 mg QD | 96.1 |
| Dexlansoprazole MR 60 mg QD | 90.9 |
The percentage was calculated as the nights that were heartburn-free out of the total number of days for which a nighttime result was marked. (NCT00321737)
Timeframe: 6 months
| Intervention | Percentage of Days (Mean) |
|---|---|
| Placebo QD | 57.7 |
| Dexlansoprazole MR 30 mg QD | 89.3 |
| Dexlansoprazole MR 60 mg QD | 86.0 |
The percentage was calculated as the nights that were heartburn-free out of the total number of days for which a nighttime result was marked. (NCT00321737)
Timeframe: 6 months
| Intervention | Percentage of Days (Median) |
|---|---|
| Placebo QD | 71.7 |
| Dexlansoprazole MR 30 mg QD | 98.9 |
| Dexlansoprazole MR 60 mg QD | 96.2 |
Crude rates analyzed maintenance of healed EE from baseline of this study and considered prematurely discontinued subjects as relapsed. (NCT00321737)
Timeframe: 6 months
| Intervention | Percentage of Subjects (Number) |
|---|---|
| Placebo QD | 14.3 |
| Dexlansoprazole MR 30 mg QD | 66.4 |
| Dexlansoprazole MR 60 mg QD | 66.4 |
Percentage of subjects who maintained complete healing of erosive esophagitis as assessed by endoscopy. In the life table method, subjects without post-baseline endoscopy were included as censored; subjects who did not have a recurrence of EE and did not complete the study were also considered censored. (NCT00321737)
Timeframe: 6 months
| Intervention | Percentage of Subjects (Number) |
|---|---|
| Placebo QD | 27.2 |
| Dexlansoprazole MR 30 mg QD | 74.9 |
| Dexlansoprazole MR 60 mg QD | 82.5 |
The percentage was calculated as the days that were heartburn-free out of the total number of days for which either a daytime or nighttime result was marked (NCT00255151)
Timeframe: 6 months
| Intervention | Percentage of Days (Mean) |
|---|---|
| Placebo QD | 29.5 |
| Dexlansoprazole MR 60 mg QD | 79.7 |
| Dexlansoprazole MR 90 mg QD | 79.2 |
The percentage was calculated as the days that were heartburn-free out of the total number of days for which either a daytime or nighttime result was reported. (NCT00255151)
Timeframe: 6 months
| Intervention | Percentage of Days (Median) |
|---|---|
| Placebo QD | 19.2 |
| Dexlansoprazole MR 60 mg QD | 95.8 |
| Dexlansoprazole MR 90 mg QD | 94.4 |
The percentage was calculated as the nights that were heartburn-free out of the total number of days for which a nighttime result was marked. (NCT00255151)
Timeframe: 6 months
| Intervention | Percentage of Days (Mean) |
|---|---|
| Placebo QD | 48.3 |
| Dexlansoprazole MR 60 mg QD | 87.1 |
| Dexlansoprazole MR 90 mg QD | 85.4 |
The percentage was calculated as the nights that were heartburn-free out of the total number of days for which a nighttime result was marked. (NCT00255151)
Timeframe: 6 months
| Intervention | Percentage of Days (Median) |
|---|---|
| Placebo QD | 50.0 |
| Dexlansoprazole MR 60 mg QD | 98.3 |
| Dexlansoprazole MR 90 mg QD | 97.1 |
Crude rates analyzed maintenance of healed EE from baseline of this study and considered prematurely discontinued subjects as relapsed. (NCT00255151)
Timeframe: 6 months
| Intervention | Percentage of Subjects (Number) |
|---|---|
| Placebo QD | 14.3 |
| Dexlansoprazole MR 60 mg QD | 66.4 |
| Dexlansoprazole MR 90 mg QD | 64.5 |
Percentage of subjects who maintained complete healing of erosive esophagitis as assessed by endoscopy. In the life table method, subjects without post-baseline endoscopy were included as censored; subjects who did not have a recurrence of EE and did not complete the study were also considered censored. (NCT00255151)
Timeframe: 6 months
| Intervention | Percentage of Subjects (Number) |
|---|---|
| Placebo QD | 25.7 |
| Dexlansoprazole MR 60 mg QD | 86.6 |
| Dexlansoprazole MR 90 mg QD | 82.1 |
The percentage was calculated as the days that were heartburn-free out of the total number of days for which either a daytime or nighttime result was marked (NCT00255164)
Timeframe: 6 months
| Intervention | Percentage of Days (Mean) |
|---|---|
| Placebo QD | 29.5 |
| Dexlansoprazole MR 60 mg QD | 79.7 |
| Dexlansoprazole MR 90 mg QD | 79.2 |
The percentage was calculated as the days that were heartburn-free out of the total number of days for which either a daytime or nighttime result was reported. (NCT00255164)
Timeframe: 6 months
| Intervention | Percentage of Days (Median) |
|---|---|
| Placebo QD | 19.2 |
| Dexlansoprazole MR 60 mg QD | 95.8 |
| Dexlansoprazole MR 90 mg QD | 94.4 |
The percentage was calculated as the nights that were heartburn-free out of the total number of days for which a nighttime result was marked. (NCT00255164)
Timeframe: 6 months
| Intervention | Percentage of Days (Mean) |
|---|---|
| Placebo QD | 48.3 |
| Dexlansoprazole MR 60 mg QD | 87.1 |
| Dexlansoprazole MR 90 mg QD | 85.4 |
The percentage was calculated as the nights that were heartburn-free out of the total number of days for which a nighttime result was marked. (NCT00255164)
Timeframe: 6 months
| Intervention | Percentage of Days (Median) |
|---|---|
| Placebo QD | 50.0 |
| Dexlansoprazole MR 60 mg QD | 98.3 |
| Dexlansoprazole MR 90 mg QD | 97.1 |
Crude rates analyzed maintenance of healed EE from baseline of this study and considered prematurely discontinued subjects as relapsed. (NCT00255164)
Timeframe: 6 months
| Intervention | Percentage of Subjects (Number) |
|---|---|
| Placebo QD | 14.3 |
| Dexlansoprazole MR 60 mg QD | 66.4 |
| Dexlansoprazole MR 90 mg QD | 64.5 |
Percentage of subjects who maintained complete healing of erosive esophagitis as assessed by endoscopy. In the life table method, subjects without post-baseline endoscopy were included as censored; subjects who did not have a recurrence of EE and did not complete the study were also considered censored. (NCT00255164)
Timeframe: 6 months
| Intervention | Percentage of Subjects (Number) |
|---|---|
| Placebo QD | 25.7 |
| Dexlansoprazole MR 60 mg QD | 86.6 |
| Dexlansoprazole MR 90 mg QD | 82.1 |
Percentage calculated by the number of heartburn-free nights out of the total number of nights during the treatment period with a diary entry indicating presence or absence of nighttime heartburn in subjects who had ≥1 diary entry indicating presence or absence of nighttime heartburn, as indicated by the subject's daily diary. Subjects indicate the presence (Yes/No) of nocturnal heartburn symptoms in a Daily Electronic Diary. Nights missing diary results were excluded from the numerator and denominator. (NCT00627016)
Timeframe: 4 Weeks
| Intervention | Percentage of nights (Median) |
|---|---|
| Placebo | 35.7 |
| Dexlansoprazole 30 mg QD | 73.1 |
Relief of nighttime heartburn was defined as 6 of 7 nights with no heartburn and at most 1 night with mild heartburn; lack of relief of nighttime heartburn was defined as 2 or more out of 7 nights with heartburn, or 1 night with at least moderate heartburn. Subjects indicate the presence and severity (mild, moderate, severe, or very severe) of nocturnal heartburn in a Daily Electronic Diary. The percentage was calculated as the number of subjects with relief of nighttime heartburn divided by the number of subjects whose relief status could be determined. (NCT00627016)
Timeframe: Last 7 days of treatment
| Intervention | Percentage of participants (Number) |
|---|---|
| Placebo | 19.6 |
| Dexlansoprazole 30 mg QD | 47.5 |
Relief of GERD-associated sleep disturbance was defined as 6 of 7 nights with no GERD associated sleep disturbances; lack of relief of GERD-associated sleep disturbance was defined as 2 or more out of 7 nights with GERD-associated sleep disturbance. Subjects indicate the presence (Yes/No) of GERD associated sleep disturbance in a Daily Electronic Diary. The percentage was calculated as the number of subjects with relief of GERD-associated sleep disturbance divided by the number of subjects whose relief status could be determined. (NCT00627016)
Timeframe: Last 7 days of treatment
| Intervention | Percentage of participants (Number) |
|---|---|
| Placebo | 47.9 |
| Dexlansoprazole 30 mg QD | 69.7 |
PAGI-SYM is a 20-item self-reported questionnaire that measures symptom severity of upper gastrointestinal disorders across six subscales (nausea/vomiting, fullness/early satiety, bloating, upper abdominal pain, lower abdominal pain, heartburn/regurgitation) which are summarized by individual subscale scores and a total score. The items are rated on a 6-point Likert scale with subscale and total score ranging from 0 (none) to 5 (very severe). Higher scores indicate higher symptom severity and thus negative changes from baseline indicate decrease in symptom severity. (NCT00847808)
Timeframe: Baseline and Week 6.
| Intervention | units on a scale (Mean) |
|---|---|
| Dexlansoprazole MR QD | -0.20 |
PAGI-SYM is a 20-item self-reported questionnaire that measures symptom severity of upper gastrointestinal disorders across six subscales (nausea/vomiting, fullness/early satiety, bloating, upper abdominal pain, lower abdominal pain, heartburn/regurgitation) which are summarized by individual subscale scores and a total score. The items are rated on a 6-point Likert scale with subscale and total score ranging from 0 (none) to 5 (very severe). Higher scores indicate higher symptom severity and thus negative changes from baseline indicate decrease in symptom severity. (NCT00847808)
Timeframe: Baseline and Week 6.
| Intervention | units on a scale (Mean) |
|---|---|
| Dexlansoprazole MR QD | -0.10 |
PAGI-SYM is a 20-item self-reported questionnaire that measures symptom severity of upper gastrointestinal disorders across six subscales (nausea/vomiting, fullness/early satiety, bloating, upper abdominal pain, lower abdominal pain, heartburn/regurgitation) which are summarized by individual subscale scores and a total score. The items are rated on a 6-point Likert scale with subscale and total score ranging from 0 (none) to 5 (very severe). Higher scores indicate higher symptom severity and thus negative changes from baseline indicate decrease in symptom severity. (NCT00847808)
Timeframe: Baseline and Week 6.
| Intervention | units on a scale (Mean) |
|---|---|
| Dexlansoprazole MR QD | -0.14 |
PAGI-SYM is a 20-item self-reported questionnaire that measures symptom severity of upper gastrointestinal disorders across six subscales (nausea/vomiting, fullness/early satiety, bloating, upper abdominal pain, lower abdominal pain, heartburn/regurgitation) which are summarized by individual subscale scores and a total score. The items are rated on a 6-point Likert scale with subscale and total score ranging from 0 (none) to 5 (very severe). Higher scores indicate higher symptom severity and thus negative changes from baseline indicate decrease in symptom severity. (NCT00847808)
Timeframe: Baseline and Week 6.
| Intervention | units on a scale (Mean) |
|---|---|
| Dexlansoprazole MR QD | -0.03 |
PAGI-SYM is a 20-item self-reported questionnaire that measures symptom severity of upper gastrointestinal disorders across six subscales (nausea/vomiting, fullness/early satiety, bloating, upper abdominal pain, lower abdominal pain, heartburn/regurgitation) which are summarized by individual subscale scores and a total score. The items are rated on a 6-point Likert scale with subscale and total score ranging from 0 (none) to 5 (very severe). Higher scores indicate higher symptom severity and thus negative changes from baseline indicate decrease in symptom severity. (NCT00847808)
Timeframe: Baseline and Week 6.
| Intervention | units on a scale (Mean) |
|---|---|
| Dexlansoprazole MR QD | 0.00 |
PAGI-SYM is a 20-item self-reported questionnaire that measures symptom severity of upper gastrointestinal disorders across six subscales (nausea/vomiting, fullness/early satiety, bloating, upper abdominal pain, lower abdominal pain, heartburn/regurgitation) which are summarized by individual subscale scores and a total score. The items are rated on a 6-point Likert scale with subscale and total score ranging from 0 (none) to 5 (very severe). Higher scores indicate higher symptom severity and thus negative changes from baseline indicate decrease in symptom severity. (NCT00847808)
Timeframe: Baseline and Week 6.
| Intervention | units on a scale (Mean) |
|---|---|
| Dexlansoprazole MR QD | -0.09 |
PAGI-SYM is a 20-item self-reported questionnaire that measures symptom severity of upper gastrointestinal disorders across six subscales (nausea/vomiting, fullness/early satiety, bloating, upper abdominal pain, lower abdominal pain, heartburn/regurgitation) which are summarized by individual subscale scores and a total score. The items are rated on a 6-point Likert scale with subscale and total score ranging from 0 (none) to 5 (very severe). Higher scores indicate higher symptom severity and thus negative changes from baseline indicate decrease in symptom severity. (NCT00847808)
Timeframe: Baseline and Week 6.
| Intervention | units on a scale (Mean) |
|---|---|
| Dexlansoprazole MR QD | -0.08 |
PAGI-QOL is a 30-item self-reported instrument assessing health-related quality of life impact of upper gastrointestinal disorders. It includes 30 items across five subscales (daily activities, clothing, diet/food habits, relationship, psychological well-being and distress), scored on a 6-point Likert scale with subscale and total score ranging from 0 (none) to 5 (all the time). For reporting purposes, the scores are reversed and higher scores reflect improved quality of life and positive changes from baseline indicate improved quality of life. (NCT00847808)
Timeframe: Baseline and Week 6.
| Intervention | units on a scale (Mean) |
|---|---|
| Dexlansoprazole MR QD | 0.02 |
PAGI-QOL is a 30-item self-reported instrument assessing health-related quality of life impact of upper gastrointestinal disorders. It includes 30 items across five subscales (daily activities, clothing, diet/food habits, relationship, psychological well-being and distress), scored on a 6-point Likert scale with subscale and total score ranging from 0 (none) to 5 (all the time). For reporting purposes, the scores are reversed and higher scores reflect improved quality of life and positive changes from baseline indicate improved quality of life. (NCT00847808)
Timeframe: Baseline and Week 6.
| Intervention | units on a scale (Mean) |
|---|---|
| Dexlansoprazole MR QD | 0.05 |
PAGI-QOL is a 30-item self-reported instrument assessing health-related quality of life impact of upper gastrointestinal disorders. It includes 30 items across five subscales (daily activities, clothing, diet/food habits, relationship, psychological well-being and distress), scored on a 6-point Likert scale with subscale and total score ranging from 0 (none) to 5 (all the time). For reporting purposes, the scores are reversed and higher scores reflect improved quality of life and positive changes from baseline indicate improved quality of life. (NCT00847808)
Timeframe: Baseline and Week 6.
| Intervention | units on a scale (Mean) |
|---|---|
| Dexlansoprazole MR QD | 0.27 |
PAGI-QOL is a 30-item self-reported instrument assessing health-related quality of life impact of upper gastrointestinal disorders. It includes 30 items across five subscales (daily activities, clothing, diet/food habits, relationship, psychological well-being and distress), scored on a 6-point Likert scale with subscale and total score ranging from 0 (none) to 5 (all the time). For reporting purposes, the scores are reversed and higher scores reflect improved quality of life and positive changes from baseline indicate improved quality of life. (NCT00847808)
Timeframe: Baseline and Week 6.
| Intervention | units on a scale (Mean) |
|---|---|
| Dexlansoprazole MR QD | 0.03 |
PAGI-QOL is a 30-item self-reported instrument assessing health-related quality of life impact of upper gastrointestinal disorders. It includes 30 items across five subscales (daily activities, clothing, diet/food habits, relationship, psychological well-being and distress), scored on a 6-point Likert scale with subscale and total score ranging from 0 (none) to 5 (all the time). For reporting purposes, the scores are reversed and higher scores reflect improved quality of life and positive changes from baseline indicate improved quality of life. (NCT00847808)
Timeframe: Baseline and Week 6.
| Intervention | units on a scale (Mean) |
|---|---|
| Dexlansoprazole MR QD | 0.10 |
PAGI-QOL is a 30-item self-reported instrument assessing health-related quality of life impact of upper gastrointestinal disorders. It includes 30 items across five subscales (daily activities, clothing, diet/food habits, relationship, psychological well-being and distress), scored on a 6-point Likert scale with subscale and total score ranging from 0 (none) to 5 (all the time). For reporting purposes, the scores are reversed and higher scores reflect improved quality of life and positive changes from baseline indicate improved quality of life. (NCT00847808)
Timeframe: Baseline and Week 6.
| Intervention | units on a scale (Mean) |
|---|---|
| Dexlansoprazole MR QD | 0.09 |
Well-controlled participants were defined to be participants who completed the study having at least 23 days of evaluable diary entries between Days 15 and 42, inclusive, and had ≤4 occurrences of heartburn during this period. (NCT00847808)
Timeframe: Week 3 through Week 6
| Intervention | percent of participants (Number) |
|---|---|
| Dexlansoprazole MR QD | 88 |
4 reviews available for lansoprazole and Heartburn
| Article | Year |
|---|---|
Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Comparative Effectiveness Research; Dexlansoprazole; | 2017 |
Nocturnal gastroesophageal reflux disease: issues, implications, and management strategies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Gastroesophageal Reflux; Heartburn; Humans; Lansoprazole; O | 2008 |
Dexlansoprazole: A proton pump inhibitor with a dual delayed-release system.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Delayed-Action Preparations; Dexlansoprazole; Esop | 2010 |
Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chest Pain; Esophagus; Gastroesophageal Reflux; Heartburn; | 2011 |
36 trials available for lansoprazole and Heartburn
| Article | Year |
|---|---|
Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole.
Topics: Adult; Aged; Biopsy; Double-Blind Method; Esophagitis, Peptic; Esophagoscopy; Esophagus; Female; Gas | 2018 |
Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis.
Topics: Adult; Aged; Double-Blind Method; Esophagitis; Female; Gastroesophageal Reflux; Heartburn; Humans; L | 2019 |
Clinical characteristics and effectiveness of lansoprazole in Japanese patients with gastroesophageal reflux disease and dyspepsia.
Topics: Adult; Aged; Dyspepsia; Esophagitis, Peptic; Female; Gastroesophageal Reflux; Heartburn; Humans; Jap | 2014 |
Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dexlansoprazole; Dose-Response Relationship, Drug; Doubl | 2013 |
Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dexlansoprazole; Dose-Response Relationship, Drug; Doubl | 2013 |
Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dexlansoprazole; Dose-Response Relationship, Drug; Doubl | 2013 |
Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dexlansoprazole; Dose-Response Relationship, Drug; Doubl | 2013 |
Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dexlansoprazole; Dose-Response Relationship, Drug; Doubl | 2013 |
Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dexlansoprazole; Dose-Response Relationship, Drug; Doubl | 2013 |
Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dexlansoprazole; Dose-Response Relationship, Drug; Doubl | 2013 |
Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dexlansoprazole; Dose-Response Relationship, Drug; Doubl | 2013 |
Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dexlansoprazole; Dose-Response Relationship, Drug; Doubl | 2013 |
Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dexlansoprazole; Dose-Response Relationship, Drug; Doubl | 2013 |
Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dexlansoprazole; Dose-Response Relationship, Drug; Doubl | 2013 |
Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dexlansoprazole; Dose-Response Relationship, Drug; Doubl | 2013 |
Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dexlansoprazole; Dose-Response Relationship, Drug; Doubl | 2013 |
Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dexlansoprazole; Dose-Response Relationship, Drug; Doubl | 2013 |
Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dexlansoprazole; Dose-Response Relationship, Drug; Doubl | 2013 |
Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dexlansoprazole; Dose-Response Relationship, Drug; Doubl | 2013 |
Randomized study of lafutidine vs lansoprazole in patients with mild gastroesophageal reflux disease.
Topics: Acetamides; Adult; Aged; Aged, 80 and over; Esophagitis, Peptic; Female; Gastroesophageal Reflux; He | 2016 |
Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Delayed-Action Preparations; Dexlansoprazole; Dose-Response | 2009 |
Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Esomeprazole; Female; Gastr | 2009 |
Clinical trial: lansoprazole 15 or 30 mg once daily vs. placebo for treatment of frequent nighttime heartburn in self-treating subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agen | 2009 |
Lansoprazole 15 mg once daily for 14 days is effective for treatment of frequent heartburn: results of 2 randomized, placebo-controlled, double-blind studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Cohort Studies; Double-Blin | 2009 |
Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis - maintenance of healing and symptom relief.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Dexlansoprazole; Dose-Respo | 2009 |
Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis - maintenance of healing and symptom relief.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Dexlansoprazole; Dose-Respo | 2009 |
Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis - maintenance of healing and symptom relief.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Dexlansoprazole; Dose-Respo | 2009 |
Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis - maintenance of healing and symptom relief.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Dexlansoprazole; Dose-Respo | 2009 |
[Lanzoptol efficiency for heartburn alleviation in patients with NERD].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Female; Gastric Acid; Gastric Acid | 2009 |
Patient self-treatment using lansoprazole for frequent nighttime heartburn. Commentary.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Female; Heartburn; Humans; Lansoprazole; | 2010 |
Clinical and pathophysiological consequences of on-demand treatment with PPI in endoscopy-negative reflux disease. Is rebound hypersecretion of acid a problem?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Chromogranins; Esophagitis; | 2011 |
The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Dexlansoprazole; Double-Bli | 2011 |
The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Dexlansoprazole; Double-Bli | 2011 |
The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Dexlansoprazole; Double-Bli | 2011 |
The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Dexlansoprazole; Double-Bli | 2011 |
Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Dexlansoprazole | 2012 |
Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Dexlansoprazole | 2012 |
Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Dexlansoprazole | 2012 |
Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Dexlansoprazole | 2012 |
Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Cohort Studies; Dose-Respon | 2003 |
Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid | 2003 |
On-demand PPI requirements in patients with endoscopy-negative GERD.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Capsules; Drug Administrati | 2004 |
The effect of Helicobacter pylori eradication on gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2004 |
Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Esomep | 2005 |
Helicobacter pylori eradication does not cause reflux oesophagitis in functional dyspeptic patients: a randomized, investigator-blinded, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Clarithromycin; Drug | 2005 |
Management of symptoms in step-down therapy of gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Deglutition Disorders; Endosonography; Enzyme Inhibit | 2005 |
Treatment of patients with heartburn without endoscopic evaluation: on-demand treatment after effective continuous administration of lansoprazole 15 mg.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Female | 2005 |
Treatment of patients with persistent heartburn symptoms: a double-blind, randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Double-Blind Method; Enzyme Inhibitors; Esomep | 2006 |
[Rapidity of pain relief, medication requirement and patient satisfaction with reflux treatment in the physician's office].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Cross-Over Studies; Dose-Re | 2005 |
Lansoprazole versus famotidine in symptomatic reflux esophagitis: a randomized, multicenter study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Anti-Ulcer Agents; Cross-Over Studies | 1995 |
Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Antacids; Anti-Ulcer Agents; Double-Blind Meth | 1997 |
A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Deglutition | 1998 |
Low-dose lansoprazole provides greater relief of heartburn and epigastric pain than low-dose omeprazole in patients with acid-related dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Double-Blind Me | 1999 |
Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Double-Blind Me | 1999 |
Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adult; Aged; Aged, 80 and over; Antacids; A | 2000 |
Pantoprazole versus lansoprazole in French patients with reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Meth | 2001 |
Management of heartburn in a large, randomized, community-based study: comparison of four therapeutic strategies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Cross-Over Studies; Double-Blind M | 2001 |
Does short-term treatment with proton pump inhibitors cause rebound aggravation of symptoms?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; | 2001 |
Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agen | 2001 |
Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Double-Blind Me | 2002 |
12 other studies available for lansoprazole and Heartburn
| Article | Year |
|---|---|
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index | 2013 |
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index | 2013 |
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index | 2013 |
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index | 2013 |
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index | 2013 |
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index | 2013 |
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index | 2013 |
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index | 2013 |
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index | 2013 |
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index | 2013 |
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index | 2013 |
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index | 2013 |
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index | 2013 |
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index | 2013 |
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index | 2013 |
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index | 2013 |
Signal detection theory approach to gastroesophageal reflux disease: a new method for symptom analysis of impedance-pH data.
Topics: Adult; Electric Impedance; Esophageal pH Monitoring; Esophageal Sphincter, Lower; Female; Gastroesop | 2014 |
Withdrawing PPI therapy after healing esophagitis does not worsen symptoms or cause persistent hypergastrinemia: analysis of dexlansoprazole MR clinical trial data.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Dexlansoprazole; Esophagitis; Female; Gastric | 2011 |
Acid suppression for reflux disease: "off-the-peg" or a tailored approach?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Female; Gastroesophageal Reflux; Heartburn; Humans; Lansopr | 2012 |
Symptomatic and endoscopic outcome of heartburn 3-4.5 years after starting lansoprazole therapy: a prospective study of 142 patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Endoscopy, Gastrointestinal; Esophagitis; Female; He | 2003 |
Neuropathy associated with lansoprazole treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Female; Heartburn; Humans; Lansop | 2005 |
Treatment of gastroesophageal reflux disease: to step or not to step.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Enzyme Inhibitors; Gastroesophageal Reflux; Heartburn; Hist | 2001 |
Impact of a formulary change in proton pump inhibitors on health care costs and patients' symptoms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Female; Formularies as Topic; Gastroesophageal Reflux; Heal | 2001 |
Clinical and ethical concerns about switching patient treatment to "therapeutically interchangeable" medications.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Critical Pathways; Esophagitis, Peptic; Ethics, Medical; He | 2001 |
What is the best pharmacologic approach to managing moderate to severe heartburn?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Double-Blind Method; Female; Heartburn; Histamine H2 | 2001 |
Proton pump inhibitors or surgery for gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Clinical Trials as Topic; Enzyme Inhibit | 2002 |
Laparoscopic fundoplication versus lansoprazole for gastro-oesophageal reflux disease. A pH-metric comparison.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Enzyme Inhibitors; Female; Fundop | 2002 |